Evaxion Biotech
Patrick Ott is the Clinical Director of the Melanoma Disease Center and the Center for Immuno-Oncology at Dana-Farber Cancer Institute. He also serves as an attending physician in the Department of Medicine at Brigham and Women's Hospital and has an appointment as Associate Professor at Harvard Medical School in Boston, MA. Ott has been the Principal Investigator and co-investigator in more than 30 treatment trials, including a first in man clinical trial testing a personalized neoantigen vaccine (NeoVax) in patients with melanoma.
This person is not in the org chart
This person is not in any offices
Evaxion Biotech
7 followers
Evaxion is pioneering the field of immunoinformatics, working hard to bring novel, highly effective vaccines and antibodies to patients. By converting complex immunological data into computational algorithms, Evaxion is capable of programming the immune system to fight off a variety of diseases from cancers to hard-to-treat anti-microbial resistant infections.